InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by Newman James W. Jr., Director. Director active across 1 company, notably Adial Pharmaceuticals, INC.. Cumulatively, 4 disclosures have been published. Split: 4 buys · 0 sell. Total volume traded: €98k. History available since 26 November 2021. The latest transaction was disclosed on 30 December 2021 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations4 total
10,000 shares@ US$2.6647.9% of flowCommon StockSEC:0001213900-22-000067
Ideal exit: 26 Sept 2022 (T+270)
10,000 shares@ US$2.660.79% mcap24.0% of flowCommon StockSEC:0001213900-22-000067:0
Ideal exit: 26 Sept 2022 (T+270)
10,000 shares@ US$2.850.86% mcap26.0% of flowCommon StockSEC:0001213900-21-062465:0
Ideal exit: 23 Aug 2022 (T+270)
10,000 shares@ US$2.8552.1% of flowCommon StockSEC:0001213900-21-062465
Ideal exit: 23 Aug 2022 (T+270)
4 of 4 declarations
About Newman James W. Jr.
James W. Newman Jr. is a Director at ADIAL PHARMACEUTICALS, INC. He oversees the company's activities and participates in strategic decision-making. His expertise in the pharmaceutical field allows him to make significant contributions to the company's governance.
